06628 TRANSCENTA-B
- 0.720
- +0.080+12.50%
TRANSCENTA-B News
On November 27, Chuangsheng Group-B (06628.HK) spent 0.0499 million Hong Kong dollars to repurchase 0.078 million shares.
Gelonghui November 27丨Chuangsheng Group-B (06628.HK) announced that on November 27, it spent 0.0499 million Hong Kong dollars to repurchase 0.078 million shares.
Chuangsheng Group - B (06628) spent approximately 0.0112 million Hong Kong dollars to repurchase 0.0145 million shares on November 21.
Chuangsheng Group-B (06628) announced that on November 21, 2024, approximately 0.0112 million Hong Kong dollars were spent to repurchase 1....
Chuangsheng Group - B (06628.HK) spent 0.05 million Hong Kong dollars to repurchase 0.064 million shares on November 20th.
Gelonghui, November 20丨Chuangsheng Group-B (06628.HK) announced that on November 20, it spent 0.05 million Hong Kong dollars to repurchase 0.064 million shares.
Chuang Sheng Group -B (06628.HK) spent 0.049 million Hong Kong dollars to repurchase 0.059 million shares on November 19th.
Gelonghui, November 19丨Chuangsheng Group-B (06628.HK) announced that on November 19, it spent 0.049 million HKD to repurchase 0.059 million shares, with a repurchase price of 0.83 HKD per share.
Chun Sheng Group-B (06628.HK): Announced at the ESMO 2024 Congress, the latest business progress of OSEMITAMAB (TST001) triplet therapy for the first-line treatment of inspiring efficacy data for gastric or gastroesophageal junction adenocarcinoma.
On September 19th, Changsheng Group-B (06628.HK) announced updated research data on the G-queue for the first-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma (TranStar102) using Osemitamab (TST001) in combination with Narulitinib and CAPOX. The data from this queue has consistently shown encouraging efficacy since its announcement at the ASCO 2024 conference. The study results showed that in patients with known levels of CLDN18.2 and PD-L1 expression, patients with high/medium expression of CLDN18.2 had a median progression-free survival (mPFS).
TRANSCENTA-B: 2024 INTERIM REPORT
On September 10th, Chong Sheng Group-B (06628.HK) spent 0.095 million Hong Kong dollars to repurchase 0.076 million shares.
GlueNet September 10th, Creatilon Group-B (06628.HK) announced that on September 10th, it spent 0.095 million Hong Kong dollars to repurchase 0.076 million shares.
Chuangsheng Group - B [06628] is currently trading at HKD 1.13, with a decrease of 11.72%.
As of 15:28, China Winner Group - B [06628] reported HK$1.13, down HK$0.15 or 11.72% from yesterday's closing price of HK$1.28. The trading volume was HK$0.0188 million. The highest price today was HK$1.25 and the lowest price was HK$1.13. Based on yesterday's closing price, the 10-day average price was HK$1.81 and the 50-day average price was HK$1.83. The current P/E ratio is -1.41 times and the 14-day strength index is 31.25.
Chuangsheng Group-B (06628.HK) cancelled 2.14 million shares on August 29th.
Gelonghui August 29th | Chuangsheng Group-B (06628.HK) announced that on August 29, 2024, the company cancelled 2.14 million shares repurchased.
Chuangsheng Group B (06628) issued 2.1996 million shares under the stock-based incentive plan.
Chuangsheng Group-B (06628) announced that it will issue shares in accordance with the company's stock-based incentive plan on August 29, 2024...
Press Release: Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results
Transcenta Holding Limited (Stock Code: 6628.HK) Announce 2024 Interim Results
Chuangsheng Group-B (06628): Xu Li was appointed as a non-executive director.
Chuangsheng Group-B (06628) announced that Dr. Xu Li (Dr. Xu) has been appointed as a non-executive director and auditor of the company...
Chuangsheng Group-B (06628) released its interim results, with a net loss of 0.134 billion yuan, a decrease of 43.73% year-on-year.
CSG Group-B (06628) has released its interim performance for the six months ended June 30, 2024, during which the group achieved...
Express News | Transcenta - Hy Loss RMB133.7 Mln
Express News | Transcenta Holding Limited H1 Revenue RMB 4.6 Million
TRANSCENTA-B: (1) INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024;(2) CHANGE IN USE OF PROCEEDS;(3) APPOINTMENT OF NON-EXECUTIVE DIRECTOR;AND(4) CHANGE IN THE COMPOSITION OF BOARD COMMITTEE
Chuangsheng Group-B (06628.HK) plans to hold a board of directors meeting on August 28 to approve the mid-term performance.
Chuangsheng Group-B (06628.HK) announced on August 16th that the board of directors hereby notifies that a board meeting will be held on Wednesday, August 28th, 2024 to consider and approve the group's interim performance for the six months ending on June 30th, 2024, and propose interim dividends (if any), as well as handle other matters.
TRANSCENTA-B: DATE OF BOARD MEETING
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
Analysis
Price Target
No Data
No Data